Reduced CRYL1 expression in hepatocellular carcinoma confers cell growth advantages and correlates with adverse patient prognosis

Journal of Pathology

Volumn 220, Issue 3, 2010, Pages 348-360

  Cheng, Ibis K C ^a   Ching, Arthur K K ^a   Chan, Tsz Choi ^a   Chan, Anthony W H ^a   Wong, Chun Kwok ^a   Choy, Kwong Wai ^a   Kwan, Man ^b   Lai, Paul B S ^a   Wong, Nathalie ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Array CGH; CRYL1; Hepatocellular carcinoma; Homozygous deletions; Tumour suppressor gene

Indexed keywords

CYCLIN B; CYCLIN DEPENDENT KINASE 1; GLOBULIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN CRYL1; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CHROMOSOME 13Q; CHROMOSOME 14Q; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; FLOW CYTOMETRY; GENE DELETION; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; COMPARATIVE GENOMIC HYBRIDIZATION; CRYSTALLINS; DOWN-REGULATION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 75749133638     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2644     Document Type: Article

References (44)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-543.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
3. Teo EK, Fock KM. Hepatocellular carcinoma: an Asian perspective. Dig Dis 2001;19:263-268.
4. Cramp M. HBV + HCV = HCC? Gut 1999;45:168-169.
5. Soini Y, Chia SC, Bennett WP, Groopman JD, Wang JS, DeBenedetti VM, et al. An aflatoxin-associated mutational hotspot at codon 249 in p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis 1996;17:1007-1012.
6. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155:323-333.
7. Yamashita T, Honda M, Takatori H, Nishino R, Minato H, Takamura H, et al. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J Hepatol 2009;50:100-110.
8. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36:1206- 1213.
9. Ohata K, Hamasaki K, Toriyama K, Matsumoto K, Saeki A, Yanagi K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003;97:3036-3043.
10. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Over-weight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003;348:1625-1638.
11. Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000;10:185-200.
12. Wong N, Lai P, Lee SW, Fan S, Pang E, Liew CT, et al. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol 1999;154:37-43.
13. Poon TC, Wong N, Lai PB, Rattray M, Johnson PJ, Sung JJ. A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. Gastroenterology 2006;131:1262-1270.
14. Hertz S, Rothämel T, Skawran B, Giere C, Steinemann D, Flemming P, et al. Losses of chromosome arms 4q, 8p, 13q and gain of 8q are correlated with increasing chromosomal instability in hepatocellular carcinoma. Pathobiology 2008;75:312-322.
15. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-440.
16. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-353.
17. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-1947.
18. Thiagalingam S, Lisitsyn NA, Hamaguchi M, Wigler MH, Willson JK, Markowitz SD, et al. Evaluation of the FHIT gene in colorectal cancers. Cancer Res 1996;56:2936-2939.
19. Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, et al. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nature Genet 1997;17:32-39.
20. Sharp TV, Al-Attar A, Foxler DE, Ding L, de A Vallim TQ, et al. The chromosome 3p21.3-encoded gene, LIMD1, is a critical tumor suppressor involved in human lung cancer development. Proc Natl Acad Sci U S A 2008;10:19932-19937.
21. Pang E, Wong N, Lai PB, To KF, Lau WY, Johnson PJ. Consistent chromosome 10 rearrangements in four newly established human hepatocellular carcinoma cell lines. Cancer Genet Cytogenet 2002;33:150-159.
22. Wong N, Chan KY, Macgregor PF, Lai PB, Squire JA, Beheshti B, et al. Transcriptional profiling identifies gene expression changes associated with IFN-alpha tolerance in hepatitis C-related hepatocellular carcinoma cells. Clin Cancer Res 2005;11:1319-1326.
23. Chan KY, Wong N, Lai PB, Squire JA, Macgregor PF, Beheshti B, et al. Transcriptional profiling on chromosome 19p indicated frequent downregulation of ACP5 expression in hepatocellular carcinoma. Int J Cancer 2005;114:902-908.
24. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 2008;105:4283-4288.
25. American Joint Committee on Cancer (AJCC) Website. http://www. cancerstaging.org. [accessed 8 October 2009].
26. American Type Culture Collection (ATCC) Website. http://www.atcc.org. [accessed 8 October 2009].
27. Japanese Collection of Research Bioresources (JCRB) Website. http://cellbank.nibio.go.jp. [accessed 3 October 2009].
28. Wong N, Li L, Tsang K, Lai P, To KF, Johnson PJ. Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma. J Hepatol 2002;37:633-639.
29. Lin YW, Sheu JC, Liu LY, Chen CH, Lee HS, Huang GT, et al. Loss of heterozygosity at chromosome 13q in hepatocellular carcinoma: identification of three independent regions. Eur J Cancer 1999;35:1730-1734.
30. Wong CM, Lee JM, Lau TC, Fan ST, Ng IO. Clinicopathological significance of loss of heterozygosity on chromosome 13q in hepatocellular carcinoma. Clin Cancer Res 2002;8:2266-2272.
31. Rider MA, Butz GM, Ricketts SL, Newberry ST, Grisham JW, Coleman WB. Suppression of tumorigenicity of rat liver tumor cells by human chromosome 13: evidence against the involvement of pRB and BRCA2. Int J Oncol 2002;20:235-245.
32. Higashitsuji H, Itoh K, Nagao T, Dawson S, Nonoguchi K, Kido T, et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nature Med 2000;6:96-99.
33. Ching YP, Wong CM, Chan SF, Leung TH, Ng DC, Jin DY, et al. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem 2003;278:10824-10830.
34. Chen J, Yu L, Li D, Gao Q, Wang J, Huang X, et al. Human CRYL1, a novel enzyme-crystallin overexpressed in liver and kidney and downregulated in 58% of liver cancer tissues from 60 Chinese patients, and four new homologs from other mammalians. Gene 2003;302:103-113.
35. Chen CF, Yeh SH, Chen DS, Chen PJ, Jou YS. Molecular genetic evidence supporting a novel human hepatocellular carcinoma tumor suppressor locus at 13q12.11. Genes Chromosomes Cancer 2005;44:320-328.
36. Ray ME, Wistow G, Su YA, Meltzer PS, Trent JM. AIM1, a novel non-lens member of the betagamma-crystallin superfamily, is associated with the control of tumorigenicity in human malignant melanoma. Proc Natl Acad Sci U S A 1997;94:3229-3234.
37. He YY, Liu SB, Lee WH, Zhang Y. Melanoma cell growth inhibition by βγ-CAT, which is a novel non-lens betagamma-crystallin and trefoil factor complex from frog Bombina maxima skin. Toxicon 2008;52:341-347.
38. Smits VAJ, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nature Cell Biol 2000;2:672-676.
39. 2/M transition. Biochim Biophys Acta 2001;1519:1-12.
40. Mulders JW, Hendriks W, Blankesteijn WM, Bloemendal H, De Jong WW. Lambda-crystallin, a major rabbit lens protein, is related to hydroxyacyl-coenzyme A dehydrogenases. J Biol Chem 1988;263:15462- 15466.
41. Ockner RK, Kaikaus RM, Bass NM. Fatty-acid metabolism and the pathogenesis of hepatocellular carcinoma: review and hypothesis. Hepatology 1993;18:669-676.
42. Yu S, Rao S, Reddy JK. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med 2003;3:561-572.
43. Li YZZY, Wang CH. The analysis of serum free fatty acid spectrum in 33 patients with primary hepatocellular carcinoma. J Dalian Med Univ 1997;19:134-136.
44. Spector AA. The importance of free fatty acid in tumor nutrition. Cancer Res 1967;27:1580-1586.